Clinicaltrials.gov ID
EudraCT ID
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A randomised, double-blind, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic effects of 10 days of repeat dosing of GSK1521498 in overweight or obese but otherwise healthy subjects.
Trial description: The overall purpose of this study is to see whether the drug is safe and well tolerated when given to overweight or obese but otherwise healthy volunteers for 10 days. Up to 4 groups of people will be given the drug at variable strengths. The blood levels of the drug will be measured and the effects on mood and cognition (the mental processes involved in awareness, learning and judgement) will be assesed.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:
Safety and tolerability: adverse events, blood pressure, heart rate, ECG, clinical chemistry, heamatology, urinalysis, change in reaction times, change in mood scales
Timeframe: During 10 days of repeat dosing
Obtain benchmarking data on the cognitive and mood changes induced by a single dose of up to 10mg zolpidem
Timeframe: Single occasion
Secondary outcomes:
Assess accumulation, dose proportionality and pharmacokinetics of GSK1521498: AUC (0-24), Cmax, tmax, tlag (Dose 1 only), t1/2 (Dose 10 only), trough plasma concentrations on Day 5, 7, 8, 9 and 10
Timeframe: On Day 1 and/or following 10 days of repeat dosing and trough samples on Day 5, 7, 8, 9 and 10
PK/PD relationships: cognitive and mood changes, pressure pain threshold and tolerance, heat pain threshold
Timeframe: During 10 days of reapeat dosing
Assess effects on body weight, fat mass, eating behaviour and personality traits: Bodyweight and BMI, Fat mass (ECHO-MRI), food ingested and energy intake, eating behaviour and persoality scales: Y-BOC-BE, BE, TFEQ and BIS
Timeframe: Screening, or Day -1 and Day 10
Interventions:
Enrollment:
49
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Nathan PJ, Bush MA, Tao WX, Koch A, Davies KM, Maltby K, O'Neill BV, Napolitano A, Skeggs AL, Brooke AC, Richards DB, Williams PM, Bullmore ET. Multiple dose safety, pharmacokinetics and pharmacodynamics of the Mu-opioid inverse agonist, GSK1521498. J Clin Pharmacol. 2012;52(10):1456-1467.
Medical condition
Obesity
Product
GSK1521498
Collaborators
Not applicable
Study date(s)
September 2009 to March 2010
Type
Interventional
Phase
1
Participation criteria
Sex
Female & Male
Age
18 - 60 years
Accepts healthy volunteers
Yes
- Healthy as determined by a responsible and experienced physician
- Non smoking male or female between 18 and 60 years of age inclusive
- Has clinically significant rhythm abnormalities identified during 24-hour screening Holter assessment.
- Systolic blood pressure greater than 150 mmHg and/or diastolic BP greater than 90 mmHg.
Inclusion and exclusion criteria
Inclusion criteria:
- Healthy as determined by a responsible and experienced physician
- Non smoking male or female between 18 and 60 years of age inclusive
- A female subject of child-bearing potential must use a contraception method listed in the protocol prior to the start of dosing until at least 14 days after receiving the last dose of study medication.
- Male subjects must agree to use one of the contraception methods listed in the protocol from the first dose of study medication until at least 84 days after receiving the last dose of study medication.
- BMI within the range 25 – 35 kg/m2 (inclusive).
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
- QTcB or QTcF < 450 msec.
- Suitable for repeat cannulation.
Exclusion criteria:
- Has clinically significant rhythm abnormalities identified during 24-hour screening Holter assessment.
- Systolic blood pressure greater than 150 mmHg and/or diastolic BP greater than 90 mmHg.
- Diabetes mellitus or physician-diagnosed dyslipidaemia requiring treatment
- Self-administered Beck Depression Inventory II scale total score greater than 13 or suicide question score greater than zero at screening.
- Positive pre-study drug/alcohol screen
- Positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
- Positive test for HIV antibody.
- Pregnant or lactating females
- Smoking history that includes regular use of tobacco or nicotine-containing products within 6 months prior to screening.
- A history of any thyroid dysfunction or an abnormal thyroid function test
- History of regular high level of alcohol consumption within 6 months of the study
- Participated in a clinical trial involving an investigational product within 90 days
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John’s Wort) within 7 days prior to the first dose of study medication
- History of any gastrointestinal or hepatic conditions or procedures that could affect absorption of the investigational product.
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that contraindicates participation.
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
- Unwillingness or inability to follow the procedures outlined in the protocol, including abstaining from consumption of caffeine-or xanthine containing products for 24 hours prior to dosing until the post-dose assessment, use of illicit drugs, refrain from alcohol for 24 hours prior to dosing until final post-dose assessment,, consumption of red wine, seville oranges, grapefruit or grapefruit juice from 7 days prior to the first dose of study medication until after collection of the final pharmacokinetic blood sample.
- Any finding that would preclude safe use of Echo MRI scanning. These include: a history of panic attacks and/or claustrophobia, pacemaker, implanted hearing aid, metallic body piercing and/or other metal implants that cannot be removed, the opinion of the Investigator the subject exceeds size limitations for the instrument.
- Mentally or legally incapacitated
Trial location(s)
Location
GSK Investigational Site
Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ
Status
Study Complete
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2010-09-03
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereResults for study 111849 can be found on the GSK Clinical Study Register.
Click hereAccess to clinical trial data by researchers
Visit website